论文部分内容阅读
目的:探讨美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎(UC)的临床疗效及对患者TNF-α、IL-8及IL-10水平的影响。方法:选择2013年1月~2014年1月我院收治的UC患者60例,随机分为研究组与对照组,每组30例。对照组患者应用美沙拉嗪治疗,研究组在此基础上联合双歧三联活菌治疗。观察两组临床疗效、血清TNF-α、IL-8及IL-10水平变化及药物不良反应。结果:研究组治疗的总有效率为86.67%,显著高于对照组的63.33%(P<0.05);治疗后,两组TNF-α、IL-8水平显著降低,IL-10水平显著升高(均P<0.01),研究组TNF-α、IL-8显著低于对照组,IL-10水平显著高于对照组(均P<0.05);研究组不良反应发生率为6.67%,明显低于对照组的33.33%(P<0.05)。结论:美沙拉嗪联合双歧三联活菌对UC患者黏膜的保护作用显著,且有效抑制UC相关的炎性反应,安全可靠,适于临床推广与应用。
Objective: To investigate the clinical efficacy of mesalazine combined with bifidobacterium triple therapy in the treatment of ulcerative colitis (UC) and its effect on the levels of TNF-α, IL-8 and IL-10 in patients. Methods: Sixty UC patients admitted to our hospital from January 2013 to January 2014 were randomly divided into study group and control group, with 30 cases in each group. The control group of patients with mesalazine treatment, the study group on this basis combined with live bifidobacteria treatment. The clinical efficacy, serum TNF-α, IL-8 and IL-10 levels and adverse drug reactions were observed. Results: The total effective rate of study group was 86.67%, which was significantly higher than that of control group (63.33%, P <0.05). After treatment, the levels of TNF-α and IL-8 were significantly decreased and the level of IL-10 was significantly increased (All P <0.01). The levels of TNF-α and IL-8 in the study group were significantly lower than those in the control group, and the levels of IL-10 in the study group were significantly higher than those in the control group (all P <0.05). The incidence of adverse reactions in the study group was 6.67% 33.33% of the control group (P <0.05). Conclusion: Mesalazine combined with Bifidobacterium triple viable can significantly protect mucosa of patients with UC and effectively suppress the UC-related inflammatory reaction, which is safe and reliable and is suitable for clinical application and promotion.